Unmet Need Is Not Enough: US FDA AdComm Rejects Levo’s Carbetocin For Prader Willi Syndrome

Patient representative was lone ‘yes’ vote, and even she acknowledged using a broad interpretation of ‘substantial evidence.’ The only route forward for Levo may be a new trial, though expanded access could be an option in the near term.